BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 26207111)

  • 1. Patterns of care study of brachytherapy in New South Wales: malignancies of the uterine corpus.
    Thompson SR; Delaney GP; Gabriel GS; Barton MB
    J Contemp Brachytherapy; 2015 Jun; 7(3):224-30. PubMed ID: 26207111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of care study of brachytherapy in New South Wales: cervical cancer treatment quality depends on caseload.
    Thompson SR; Delaney GP; Gabriel GS; Barton MB
    J Contemp Brachytherapy; 2014 Mar; 6(1):28-32. PubMed ID: 24790619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate brachytherapy in New South Wales: patterns of care study and impact of caseload on treatment quality.
    Thompson SR; Delaney GP; Gabriel GS; Izard MA; Hruby G; Jagavkar R; Bucci J; Barton MB
    J Contemp Brachytherapy; 2015 Jan; 6(4):344-9. PubMed ID: 25834577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimation of the optimal brachytherapy utilization rate in the treatment of gynecological cancers and comparison with patterns of care.
    Thompson SR; Delaney GP; Gabriel GS; Jacob S; Das P; Barton MB
    Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):400-5. PubMed ID: 22658439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation of the optimal brachytherapy utilisation rate in the treatment of vaginal cancer and comparison with patterns of care.
    Thompson SR; Delaney GP; Gabriel GS; Jacob S; Barton MB
    J Med Imaging Radiat Oncol; 2012 Aug; 56(4):483-9. PubMed ID: 22883660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimation of optimal brachytherapy utilization rate in the treatment of malignancies of the uterine corpus by a review of clinical practice guidelines and the primary evidence.
    Thompson SR; Delaney G; Gabriel GS; Jacob S; Das P; Barton M
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):849-58. PubMed ID: 18448273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimation of the optimal brachytherapy utilization rate in the treatment of carcinoma of the uterine cervix: review of clinical practice guidelines and primary evidence.
    Thompson S; Delaney G; Gabriel GS; Jacob S; Das P; Barton M
    Cancer; 2006 Dec; 107(12):2932-41. PubMed ID: 17109449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of radiotherapy practice for patients with squamous carcinoma of the uterine cervix: patterns of care study.
    Eifel PJ; Moughan J; Owen J; Katz A; Mahon I; Hanks GE
    Int J Radiat Oncol Biol Phys; 1999 Jan; 43(2):351-8. PubMed ID: 10030261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary radiotherapy for nonsurgically managed Stage I endometrial cancer: Utilization and impact of brachytherapy.
    Gill BS; Chapman BV; Hansen KJ; Sukumvanich P; Beriwal S
    Brachytherapy; 2015; 14(3):373-9. PubMed ID: 25600451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiobiological optimization comparison between pulse-dose-rate and high-dose-rate brachytherapy in patients with locally advanced cervical cancer.
    Annede P; Dumas I; Schernberg A; Tailleur A; Fumagalli I; Bockel S; Mignot F; Kissel M; Deutsch E; Haie-Meder C; Chargari C
    Brachytherapy; 2019; 18(3):370-377. PubMed ID: 30797698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Image-based three-dimensional conformal brachytherapy for medically inoperable endometrial carcinoma.
    Gill BS; Kim H; Houser C; Olsen A; Kelley J; Edwards RP; Comerci J; Sukumvanich P; Olawaiye AB; Huang M; Courtney-Brooks M; Beriwal S
    Brachytherapy; 2014; 13(6):542-7. PubMed ID: 25127122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does an Algorithmic Approach to Using Brachytherapy and External Beam Radiation Result in Good Function, Local Control Rates, and Low Morbidity in Patients With Extremity Soft Tissue Sarcoma?
    Klein J; Ghasem A; Huntley S; Donaldson N; Keisch M; Conway S
    Clin Orthop Relat Res; 2018 Mar; 476(3):634-644. PubMed ID: 29443850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of second malignancies in prostate cancer patients treated with low-dose-rate brachytherapy and radical prostatectomy.
    Hamilton SN; Tyldesley S; Hamm J; Jiang WN; Keyes M; Pickles T; Lapointe V; Kahnamelli A; McKenzie M; Miller S; Morris WJ
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):934-41. PubMed ID: 25240272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose to the non-involved uterine corpus with MRI guided brachytherapy in locally advanced cervical cancer.
    Sapru S; Mohamed S; Fokdal L; Nkiwane K; Swamidas J; Mahantshetty U; Kirisits C; Pötter R; Christian Lindegaard J; Tanderup K
    Radiother Oncol; 2013 Apr; 107(1):93-8. PubMed ID: 23490270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reporting and validation of gynaecological Groupe Euopeen de Curietherapie European Society for Therapeutic Radiology and Oncology (ESTRO) brachytherapy recommendations for MR image-based dose volume parameters and clinical outcome with high dose-rate brachytherapy in cervical cancers: a single-institution initial experience.
    Mahantshetty U; Swamidas J; Khanna N; Engineer R; Merchant NH; Deshpande DD; Shrivastava S
    Int J Gynecol Cancer; 2011 Aug; 21(6):1110-6. PubMed ID: 21633296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An analysis of simulation for adjuvant intracavitary high-dose-rate brachytherapy in early-stage endometrial cancer.
    Barney BM; MacDonald OK; Lee CM; Rankin J; Gaffney DK
    Brachytherapy; 2007; 6(3):201-6. PubMed ID: 17681241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Image-guided brachytherapy for cervical cancer: a Canadian Brachytherapy Group survey.
    Pavamani S; D'Souza DP; Portelance L; Craighead PS; Pearce AG; Traptow LL; Doll CM
    Brachytherapy; 2011; 10(5):345-51. PubMed ID: 21345744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second primary malignancies after radiotherapy including HDR (252)Cf brachytherapy for cervical cancer.
    Samerdokiene V; Valuckas KP; Janulionis E; Atkocius V; Rivard MJ
    Brachytherapy; 2015; 14(6):898-904. PubMed ID: 26194049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
    Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A volumetric analysis of GTV
    Jastaniyah N; Yoshida K; Tanderup K; Lindegaard JC; Sturdza A; Kirisits C; Šegedin B; Mahantshetty U; Rai B; Jürgenliemk-Schulz IM; Haie-Meder C; Banerjee S; Pötter R;
    Radiother Oncol; 2016 Sep; 120(3):404-411. PubMed ID: 27452409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.